Your browser doesn't support javascript.
loading
Investigation of the Efficacy and Safety of Nivolumab in Recurrent and Metastatic Nasopharyngeal Carcinoma.
Sato, Hiroki; Fushimi, Chihiro; Okada, Takuro; Matsuki, Takashi; Kondo, Takahito; Omura, G O; Miura, Kouki; Yamashita, Taku; Okamoto, Isaku; Tsukahara, Kiyoaki.
Affiliation
  • Sato H; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan satohiro@tokyo-med.ac.jp.
  • Fushimi C; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Okada T; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Matsuki T; Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
  • Kondo T; Department of Otolaryngology, Head and Neck Surgery, Tokyo Medical University Hachioji Medical Center, Tokyo, Japan.
  • Omura GO; Department of Head and Neck Surgery, National Cancer Center Hospital, Tokyo, Japan.
  • Miura K; Department of Head and Neck Oncology and Surgery, International University of Health and Welfare Mita Hospital, Tokyo, Japan.
  • Yamashita T; Department of Otorhinolaryngology-Head and Neck Surgery, Kitasato University School of Medicine, Kanagawa, Japan.
  • Okamoto I; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Tsukahara K; Department of Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
In Vivo ; 34(5): 2967-2972, 2020.
Article in En | MEDLINE | ID: mdl-32871839
BACKGROUND/AIM: Nivolumab, an anti-PD-1 inhibitor, has demonstrated efficacy in patients with several types of recurrent and metastatic (R/M) squamous cell carcinoma of the head and neck. We evaluated patients with R/M-NPC receiving nivolumab. PATIENTS AND METHODS: Twelve patients with R/M-NPC were enrolled at 4 institutions. The primary endpoint was overall survival, and secondary endpoints were i) progression-free survival (PFS), ii) overall response rate (ORR), iii) disease control rate (DCR), and iv) treatment-related toxicity. RESULTS: The 1-year survival rate was 75.8%, the median PFS was 2.8 months, and the 1-year PFS rate was 33.3%. The best therapeutic response was complete response in 2, stable disease in 3 and progressive disease in 7 patients. The ORR of all patients was 16.7% and the DCR was 41.7%. CONCLUSION: Nivolumab is a useful and relatively safe second-line systemic therapy in patients with R/M-NPC, and even patients who do not respond to nivolumab may survive for a long time.
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: In Vivo Journal subject: NEOPLASIAS Year: 2020 Document type: Article Affiliation country: Japan Country of publication: Greece
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Nasopharyngeal Neoplasms / Antineoplastic Agents, Immunological Limits: Humans Language: En Journal: In Vivo Journal subject: NEOPLASIAS Year: 2020 Document type: Article Affiliation country: Japan Country of publication: Greece